oDw
ownwlno
nla
lodaeddedbyb:yS
: fwu
kAipsre
iharehA|||paaabbpbiieigeklciatlcyinh1@
2@
gmgm
aiilal.ciclo
.ocm
om
Distribution fwof fwthis fwdocument fwis fwillegal
,Chapter 1: Indications for Pulmonary Function Testing
fw fw fw fw fw fw
Test Bank
fw fw
MULTIPLE CHOICE fw
1. Who first popularized spirometry for the evaluation of pulmonary function?
fw fw fw fw fw fw fw fw fw
a. August and Marie Krogh fw fw fw
b. Alvan Barach fw
c. John Severinghaus fw
d. John Hutchinson fw
ANS: D fw fw
Hutchinson popularized the concept of using VC to assess lung function, and the names
fw fw fw fw fw fw fw fw fw fw fw fw fw
he gave to several other lung compartments are still used today.
fw fw fw fw fw fw fw fw fw fw fw
DIF: 1 REF: p. 2 fw OBJ: None MSC: f w NBRC: None fw
2. Which of the following are indications for performing spirometry?
fw fw fw fw fw fw fw fw
1. Assess the risk of lung resection. fw fw fw fw fw
2. Determine the response to bronchodilator therapy. fw fw fw fw fw
3. Assess the severity of restrictive lung disease.
fw fw fw fw fw fw
4. Quantify the extent of COPD. fw fw fw fw
a. 1 and 4 fw fw
b. 2 and 3 fw fw
c. 1, 2, and 4 fw fw fw
d. 2, 3, and 4 fw fw fw
ANS: C fw fw
Spirometry cannot assess severity of restriction; for that you need to measure lung
fw fw fw fw fw fw fw fw fw fw fw fw
volumes (see Box 1-2, Chapter 1).
fw fw fw fw fw fw
DIF: 1 REF: p. 7 fw OBJ: EL-2 MSC: f w NBRC: None fw
3. The main indication for the measurement of lung volumes is to do which of the
fw fw fw fw fw fw fw fw fw fw fw fw fw fw
following?
fw
a. Diagnose or assess the severity of restriction. fw fw fw fw fw fw
b. Evaluate the severity of pulmonary hypertension. fw fw fw fw fw
c. Determine the level of cardiopulmonary fitness. fw fw fw fw fw
d. Assess the risk of abdominal surgical procedures.
fw fw fw fw fw fw
ANS: A fw fw
The most common reason for measuring lung volumes is to identify restrictive lung
fw fw fw fw fw fw fw fw fw fw fw fw
disease. DIF:
fw fw 1 REF: p. 35 OBJ:
fw EL-2 MSC: f w NBRC:
fw None
4. DLCO measurements may be indicated to evaluate pulmonary involvement in which
fw fw fw fw fw fw fw fw fw fw
of the following systemic diseases?
fw fw fw fw fw
a. Asthma
b. Sarcoidosis
c. Exertional hypoxemia fw
DD
oDw
ownwlno
nla
lodaeddedbyb:yS
: fwu
kAipsre
iharehA|||paaabbpbiieigeklciatlcyinh1@
2@
gmgm
aiilal.ciclo
.ocm
om
Distribution fwof fwthis fwdocument fwis fwillegal
, d. Guillain-Barré syndrome fw
ANS: B fw fw
Sarcoidosis is the only systemic disease listed that affects gas exchange.
fw fw fw fw fw fw fw fw fw fw
DIF: 1 REF: p. 9 | p. 19 | p. 21 | p. 35 fw fw fw fw fw fw fw fw fw fw OBJ: EL-2
MSC: NBRC: None
fw f w fw
5. Blood gas analysis is used with patients with COPD to do which of the following?
fw fw fw fw fw fw fw fw fw fw fw fw fw fw
a. Monitor airway responsiveness. fw fw
b. Determine level of cardiopulmonary fitness. fw fw fw fw
c. Detect pulmonary hypertension. fw fw
d. Assess need for supplementary O2.fw fw fw fw
ANS: D fw fw
Blood gas analysis is most commonly used to determine the need for supplemental
fw fw fw fw fw fw fw fw fw fw fw fw
oxygen and to manage patients who require ventilatory support.
fw fw fw fw fw fw fw fw fw
DIF: 2 REF: p. 15 fw OBJ: EL-1
MSC: NBRC: CPFT 2A-2
fw f w fw fw
6. Which of the following cause emphysema?
fw fw fw fw fw
1. 1-Antitrypsin deficiency fw
2. Exposure to environmental pollutants fw fw fw
3. Radiation therapy fw
4. Cigarette smoking fw
a. 1 and 2fw fw
b. 3 and 4fw fw
c. 1, 2, and 4 fw fw fw
d. 2, 3, and 4 fw fw fw
ANS: Cfw fw
Emphysema is caused primarily by cigarette smoking. Some emphysema is caused by the
fw fw fw fw fw fw fw fw fw fw fw fw
absence of a protective enzyme. Chronic exposure to environmental pollutants can also
fw fw fw fw fw fw fw fw fw fw fw fw
contribute to the development of emphysema.
fw fw fw fw fw fw
DIF: 1 REF: p. 11 fw OBJ: EL-3 | AL-2 MSC: fw fw f w NBRC: None fw
7. An adult patient complains of chest tightness and cough whenever he jogs in cold
fw fw fw fw fw fw fw fw fw fw fw fw fw
weather. These symptoms are consistent with which of the following?
fw fw fw fw fw fw fw fw fw fw
a. Cystic fibrosis fw
b. Asthma
c. Pulmonary hypertension fw
d. Idiopathic pulmonary fibrosis fw fw
ANS: Bfw fw
Agents or events that cause an asthmatic episode are called triggers (see Box 1-7,
fw fw fw fw fw fw fw fw fw fw fw fw fw
Chapter 1). Antigens such as animal dander, pollens, and dusts are the most common
fw fw fw fw fw fw fw fw fw fw fw fw fw fw
triggers. Other common triggers include exposure to air pollutants and exercise in
fw fw fw fw fw fw fw fw fw fw fw fw
cold or dry air.
fw fw fw fw
DIF: 2 REF: p. 16 fw OBJ: EL-3 MSC: f w NBRC: None fw
DD
oDw
ownwlno
nla
lodaeddedbyb:yS
: fwu
kAipsre
iharehA|||paaabbpbiieigeklciatlcyinh1@
2@
gmgm
aiilal.ciclo
.ocm
om
Distribution fwof fwthis fwdocument fwis fwillegal
, 8. Which of the following statements concerning tumors in the upper airway is true?
fw fw fw fw fw fw fw fw fw fw fw fw
a. There may be variable or fixed obstruction.
fw fw fw fw fw fw
b. Fixed obstruction will be present. fw fw fw fw
c. Variable obstruction will be present. fw fw fw fw
d. Small airway obstruction will result.
fw fw fw fw
ANS: A fw fw
Tumors involving the upper airway may cause variable or fixed obstruction.
fw fw fw fw fw fw fw fw fw fw
DIF: 2 REF: p. 19 fw OBJ: EL-2
MSC: NBRC: CPFT 3C-3
fw f w fw fw
9. Sarcoidosis is a systemic disorder that usually causes which of the following?
fw fw fw fw fw fw fw fw fw fw fw
a. A restrictive ventilatory defect
fw fw fw
b. An obstructive ventilatory defect
fw fw fw
c. Hyperreactive airways fw
d. Primary pulmonary hypertension fw fw
ANS: A fw fw
Restriction is often associated with the following: interstitial lung diseases, including
fw fw fw fw fw fw fw fw fw fw
idiopathic fibrosis, pneumoconioses, and sarcoidosis.
fw fw fw fw fw
DIF: 1 REF: p. 19 | p. 21 OBJ: fw fw fw fw EL-3 MSC: f w NBRC: None fw
10. For which of the following conditions might pulmonary function testing be
fw fw fw fw fw fw fw fw fw fw
contraindicated?
fw
a. Vocal cord dysfunction fw fw
b. Untreated pneumothorax fw
c. Congestive heart failure (CHF) fw fw fw
d. Bronchiolitis obliterans fw
ANS: B fw fw
Pulmonary function tests are usually contraindicated in the presence of pneumothorax.
fw fw fw fw fw fw fw fw fw fw
However, undiagnosed pneumothorax may present a risk if pulmonary function studies
fw fw fw fw fw fw fw fw fw fw fw
are performed.
fw fw
DIF: 1 REF: p. 23 fw OBJ: EL-4
MSC: NBRC: CPFT 2B-6
fw f w fw fw
11. Which of the following correctly describe(s) appropriate physical measurements
fw fw fw fw fw fw fw fw
before pulmonary function testing?
fw fw fw fw
1. Actual body weight should be used to calculate predicted values.
fw fw fw fw fw fw fw fw fw
2. Standing height should be measured when the patient is barefoot.
fw fw fw fw fw fw fw fw fw
3. Arm span should be used instead of height for a patient with kyphosis.
fw fw fw fw fw fw fw fw fw fw fw fw
4. Age should be recorded to the nearest decade (10 years).
fw fw fw fw fw fw fw fw fw
a. 1 only fw
b. 2 and 3 fw fw
c. 1, 2, and 4 fw fw fw
d. 1, 2, 3, and fw fw fw
4 ANS:
fw fw f w B
DD
oDw
ownwlno
nla
lodaeddedbyb:yS
: fwu
kAipsre
iharehA|||paaabbpbiieigeklciatlcyinh1@
2@
gmgm
aiilal.ciclo
.ocm
om
Distribution fwof fwthis fwdocument fwis fwillegal